Physician profile
Andrew Engel
NPI 1194879445
$1,681.87
in general payments reported to CMS, 2019-2025
22 companies · $568 in 2025
The $568 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $154 · 2021: $15.22 · 2023: $253 · 2024: $500 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $289.65 | 2023-2025 | Veozah |
| Sage Therapeutics, LLC | $268.74 | 2024-2025 | Zurzuvae |
| Organon LLC | $191.81 | 2023-2025 | Nexplanon |
| Abbvie INC. | $134.08 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $92.27 | 2023-2024 | Myfembree |
| Coopersurgical, INC. | $90.59 | 2019-2024 | Paragard T 380a |
| Dysis Medical, INC. | $83.32 | 2020 | |
| Daiichi Sankyo INC. | $65.38 | 2024 | Injectafer |
| Pfizer INC. | $59.00 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.78 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $54.67 | 2019-2020 | |
| Lupin INC. | $49.70 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $47.36 | 2025 | |
| Millicent US INC | $41.73 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Exact Sciences Corporation | $31.26 | 2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $25.20 | 2025 | |
| Exeltis, USA INC. | $19.81 | 2025 | Slynd |
| Hologic Sales and Service, LLC | $18.27 | 2024 | Novasure |
| Seqirus USA INC | $17.01 | 2024 | Flucelvax, Fluad |
| Evofem Biosciences, INC. | $15.22 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.60 | 2025 | Qelbree |
| Boston Scientific Corporation | $14.42 | 2023 | Rezum Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Engel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.